274 related articles for article (PubMed ID: 29466360)
1. Combining metformin and esomeprazole is additive in reducing sFlt-1 secretion and decreasing endothelial dysfunction - implications for treating preeclampsia.
Kaitu'u-Lino TJ; Brownfoot FC; Beard S; Cannon P; Hastie R; Nguyen TV; Binder NK; Tong S; Hannan NJ
PLoS One; 2018; 13(2):e0188845. PubMed ID: 29466360
[TBL] [Abstract][Full Text] [Related]
2. Combining metformin and sulfasalazine additively reduces the secretion of antiangiogenic factors from the placenta: Implications for the treatment of preeclampsia.
Brownfoot FC; Hastie R; Hannan NJ; Cannon P; Nguyen TV; Tuohey L; Cluver C; Tong S; Kaitu'u-Lino TJ
Placenta; 2020 Jun; 95():78-83. PubMed ID: 32452405
[TBL] [Abstract][Full Text] [Related]
3. Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction.
Brownfoot FC; Hastie R; Hannan NJ; Cannon P; Tuohey L; Parry LJ; Senadheera S; Illanes SE; Kaitu'u-Lino TJ; Tong S
Am J Obstet Gynecol; 2016 Mar; 214(3):356.e1-356.e15. PubMed ID: 26721779
[TBL] [Abstract][Full Text] [Related]
4. Esomeprazole and sulfasalazine in combination additively reduce sFlt-1 secretion and diminish endothelial dysfunction: potential for a combination treatment for preeclampsia.
Binder NK; Brownfoot FC; Beard S; Cannon P; Nguyen TV; Tong S; Kaitu'u-Lino TJ; Hannan NJ
Pregnancy Hypertens; 2020 Oct; 22():86-92. PubMed ID: 32758704
[TBL] [Abstract][Full Text] [Related]
5. Proton Pump Inhibitors Decrease Soluble fms-Like Tyrosine Kinase-1 and Soluble Endoglin Secretion, Decrease Hypertension, and Rescue Endothelial Dysfunction.
Onda K; Tong S; Beard S; Binder N; Muto M; Senadheera SN; Parry L; Dilworth M; Renshall L; Brownfoot F; Hastie R; Tuohey L; Palmer K; Hirano T; Ikawa M; Kaitu'u-Lino T; Hannan NJ
Hypertension; 2017 Mar; 69(3):457-468. PubMed ID: 28115513
[TBL] [Abstract][Full Text] [Related]
6. Effects of simvastatin, rosuvastatin and pravastatin on soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sENG) secretion from human umbilical vein endothelial cells, primary trophoblast cells and placenta.
Brownfoot FC; Tong S; Hannan NJ; Hastie R; Cannon P; Kaitu'u-Lino TJ
BMC Pregnancy Childbirth; 2016 May; 16():117. PubMed ID: 27207105
[TBL] [Abstract][Full Text] [Related]
7. Melatonin enhances antioxidant molecules in the placenta, reduces secretion of soluble fms-like tyrosine kinase 1 (sFLT) from primary trophoblast but does not rescue endothelial dysfunction: An evaluation of its potential to treat preeclampsia.
Hannan NJ; Binder NK; Beard S; Nguyen TV; Kaitu'u-Lino TJ; Tong S
PLoS One; 2018; 13(4):e0187082. PubMed ID: 29641523
[TBL] [Abstract][Full Text] [Related]
8. Effects of Pravastatin on Human Placenta, Endothelium, and Women With Severe Preeclampsia.
Brownfoot FC; Tong S; Hannan NJ; Binder NK; Walker SP; Cannon P; Hastie R; Onda K; Kaitu'u-Lino TJ
Hypertension; 2015 Sep; 66(3):687-97; discussion 445. PubMed ID: 26222708
[TBL] [Abstract][Full Text] [Related]
9. Disulfiram inhibits placental soluble FMS-like tyrosine kinase-1 and soluble endoglin secretion independent of the proteasome.
Hastie R; Ye L; Hannan NJ; Brownfoot FC; Cannon P; Nguyen V; Tong S; Kaitu'u-Lino TJ
Pregnancy Hypertens; 2018 Oct; 14():125-130. PubMed ID: 30527099
[TBL] [Abstract][Full Text] [Related]
10. Procyanidin B2 ameliorates endothelial dysfunction and impaired angiogenesis via the Nrf2/PPARγ/sFlt-1 axis in preeclampsia.
Liu L; Wang R; Xu R; Chu Y; Gu W
Pharmacol Res; 2022 Mar; 177():106127. PubMed ID: 35150862
[TBL] [Abstract][Full Text] [Related]
11. Activating Transcription Factor 3 Is Reduced in Preeclamptic Placentas and Negatively Regulates sFlt-1 (Soluble fms-Like Tyrosine Kinase 1), Soluble Endoglin, and Proinflammatory Cytokines in Placenta.
Kaitu'u-Lino TJ; Brownfoot FC; Hastie R; Chand A; Cannon P; Deo M; Tuohey L; Whitehead C; Hannan NJ; Tong S
Hypertension; 2017 Nov; 70(5):1014-1024. PubMed ID: 28947613
[TBL] [Abstract][Full Text] [Related]
12. Heme Oxygenase-1 Is Not Decreased in Preeclamptic Placenta and Does Not Negatively Regulate Placental Soluble fms-Like Tyrosine Kinase-1 or Soluble Endoglin Secretion.
Tong S; Kaitu'u-Lino TJ; Onda K; Beard S; Hastie R; Binder NK; Cluver C; Tuohey L; Whitehead C; Brownfoot F; De Silva M; Hannan NJ
Hypertension; 2015 Nov; 66(5):1073-81. PubMed ID: 26324507
[TBL] [Abstract][Full Text] [Related]
13. EGFR (Epidermal Growth Factor Receptor) Signaling and the Mitochondria Regulate sFlt-1 (Soluble FMS-Like Tyrosine Kinase-1) Secretion.
Hastie R; Brownfoot FC; Pritchard N; Hannan NJ; Cannon P; Nguyen V; Palmer K; Beard S; Tong S; Kaitu'u-Lino TJ
Hypertension; 2019 Mar; 73(3):659-670. PubMed ID: 30636550
[TBL] [Abstract][Full Text] [Related]
14. Sofalcone upregulates the nuclear factor (erythroid-derived 2)-like 2/heme oxygenase-1 pathway, reduces soluble fms-like tyrosine kinase-1, and quenches endothelial dysfunction: potential therapeutic for preeclampsia.
Onda K; Tong S; Nakahara A; Kondo M; Monchusho H; Hirano T; Kaitu'u-Lino T; Beard S; Binder N; Tuohey L; Brownfoot F; Hannan NJ
Hypertension; 2015 Apr; 65(4):855-62. PubMed ID: 25667213
[TBL] [Abstract][Full Text] [Related]
15. Sulfasalazine reduces placental secretion of antiangiogenic factors, up-regulates the secretion of placental growth factor and rescues endothelial dysfunction.
Brownfoot FC; Hannan NJ; Cannon P; Nguyen V; Hastie R; Parry LJ; Senadheera S; Tuohey L; Tong S; Kaitu'u-Lino TJ
EBioMedicine; 2019 Mar; 41():636-648. PubMed ID: 30824385
[TBL] [Abstract][Full Text] [Related]
16. YC-1 reduces placental sFlt-1 and soluble endoglin production and decreases endothelial dysfunction: A possible therapeutic for preeclampsia.
Brownfoot FC; Tong S; Hannan NJ; Hastie R; Cannon P; Tuohey L; Kaitu'u-Lino TJ
Mol Cell Endocrinol; 2015 Sep; 413():202-8. PubMed ID: 26159901
[TBL] [Abstract][Full Text] [Related]
17. Effect of sildenafil citrate on circulating levels of sFlt-1 in preeclampsia.
Brownfoot FC; Tong S; Hannan NJ; Cannon P; Nguyen V; Kaitu'u-Lino TJ
Pregnancy Hypertens; 2018 Jul; 13():1-6. PubMed ID: 30177033
[TBL] [Abstract][Full Text] [Related]
18. Effects of anti-hypertensive drugs on production of soluble fms-like tyrosine kinase 1 and soluble endoglin from human normal and pre-eclamptic placentas in vitro.
Xu B; Thornton C; Tooher J; Ogle R; Lim S; Makris A; Hennessy A
Clin Exp Pharmacol Physiol; 2009 Aug; 36(8):839-42. PubMed ID: 19215236
[TBL] [Abstract][Full Text] [Related]
19. Hydroxychloroquine Mitigates the Production of 8-Isoprostane and Improves Vascular Dysfunction: Implications for Treating Preeclampsia.
Rahman RA; Murthi P; Singh H; Gurungsinghe S; Leaw B; Mockler JC; Lim R; Wallace EM
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32260307
[TBL] [Abstract][Full Text] [Related]
20. Resveratrol inhibits release of soluble fms-like tyrosine kinase (sFlt-1) and soluble endoglin and improves vascular dysfunction - implications as a preeclampsia treatment.
Hannan NJ; Brownfoot FC; Cannon P; Deo M; Beard S; Nguyen TV; Palmer KR; Tong S; Kaitu'u-Lino TJ
Sci Rep; 2017 May; 7(1):1819. PubMed ID: 28500309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
